SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000920465-20-000057
Filing Date
2020-05-04
Accepted
2020-05-01 20:23:04
Documents
5
Effectiveness Date
2020-05-04

Document Format Files

Seq Description Document Type Size
1 DEFA14A proxy2020defa14avirtualmee.htm DEFA14A 42235
2 lajolla2019proxy01page1.jpg GRAPHIC 170952
3 lajolla2019proxy01page2.jpg GRAPHIC 223328
4 lajolla2019proxy01page3.jpg GRAPHIC 78478
5 lajolla2019proxy01page4.jpg GRAPHIC 52081
  Complete submission text file 0000920465-20-000057.txt   766625
Mailing Address 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Business Address 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36282 | Film No.: 20842408
SIC: 2836 Biological Products, (No Diagnostic Substances)